Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qualia Senolytic is a multi-ingredient dietary supplement developed by Neurohacker Collective designed to support cellular health by targeting senescent cells, often referred to as "zombie cells." The formulation is a complex blend of polyphenols and botanical extracts, including fisetin, quercetin (as Quercefit phytosome), luteolin, curcumin (as HydroCurc), milk thistle (silymarin), piperlongumine (from *Piper longum*), and olive leaf extract. It is typically administered in a "pulsed" dosing regimen, such as two days per month, to promote the selective clearance of senescent cells that accumulate with age and contribute to the Senescence-Associated Secretory Phenotype (SASP), which is characterized by the release of pro-inflammatory cytokines. Clinical research, including pilot studies like NCT06953518, evaluates its efficacy in attenuating systemic inflammatory markers such as TNF-alpha, IL-1 beta, and IL-8, as well as its impact on aging-related health indicators like frailty and physical function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qualia Senolytic.